Publications by authors named "J Czernin"
Article Synopsis
- The study compares the definitions of high-volume disease (HVD) and low-volume disease (LVD) in metastatic hormone-sensitive prostate cancer (mHSPC) patients using both conventional imaging (CI) and prostate-specific membrane antigen (PSMA) PET imaging, highlighting the need for more accurate definitions for treatment decisions.
- Researchers analyzed data from 67 mHSPC patients across five international sites who had both PSMA PET and CI scans within a specific timeframe, assessing how many were classified as HVD or LVD based on each imaging method.
- Results showed a significant discrepancy in classification: 25.4% of patients were identified as HVD using CI, while 40.3% were identified as HVD using
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.